Introduction
The coxsackie and adenovirus receptor (CAR) has been identified as the primary receptor for attachment of both coxsackie B viruses and adenoviruses to the cellular membrane. [1] [2] [3] For gene therapy of human cancer cells, CAR has become of interest both due to its crucial function in adenoviral gene transfer and its potential role in cancer progression. 4, 5 Little is known about the physiological cellular function and regulatory mechanism of CAR expression in cancer cells or in normal tissues. In differentiated human or canine epithelial cells, CAR was found to be localized at basolateral cell-cell adhesions 6 and tight junctions. 7 Currently ongoing clinical trials with recombinant adenoviruses reveal that besides varying gene transfer efficiencies, one of the main problems in situ are severe immunological side reactions. 8, 9 The synthetic glucocorticoid dexamethasone is an anti-inflammatory drug and is frequently applied in supportive cancer care including clinical trials with recombinant adenoviruses. One of its anti-inflammatory mechanisms is brought about by inhibition of NF-kB activity via glucocorticoid receptor activation. 10 This study demonstrates that dexamethasone can reduce the expression level of CAR in various cancer cell lines, thereby reducing adenoviral transduction efficiency.
The first contact of adenoviruses to cell membranes is mediated by binding of the adenoviral fiber knob to CAR 11 and subsequent binding of the RGD (arg-gly-asp) motif-bearing adenoviral capsid to RGD motif-binding integrins such as integrins a5b1, avb3 and avb5. 12 Several studies tried to establish correlations between CAR or integrin expression levels and adenoviral gene transfer efficiency. [13] [14] [15] [16] [17] Despite diverging results, it was generally concluded that either loss of CAR expression or that of RGD-binding integrins was a main obstacle for efficient adenoviral gene transfer into cancer cells in cell culture. [13] [14] [15] [16] [17] For ovarian cancer cells, we noticed that even cell lines with a high level of CAR expression can be resistant against adenoviral infection due to loss of integrin avb3 expression by transcriptional silencing of the integrin b3 subunit. 17 Integrin subunit expression can be regulated by several fibrogenic and pro-inflammatory cytokines such as TGFb 18, 19 or TNFa. 20 Both TGFb and TNFa can be found at high concentrations in human cancer tissues. Here we show that TGFb and TNFa can modulate the expression of both, CAR and integrins and thereby modulate adenoviral gene transfer efficiency.
Results

Dexamethasone reduces adenoviral transgene expression
The cervical cancer cell lines HeLa and SiHa, the glioblastoma cell line U87MG, and the ovarian cancer cell line OV-UL-2 were pre-incubated with 100 nM dexamethasone overnight and transduced with a bgalactosidase-expressing adenovirus (AdGal). Figure 1 shows that dexamethasone pretreatment before adenovirus application inhibited b-galactosidase expression in HeLa, SiHa and U87MG cells, but not in OV-UL-2 cells. Dexamethasone had no effect on b-galactosidase expression when applied after adenoviral transduction (not shown). We therefore analysed whether dexamethasone induced changes in the expression level of primary (CAR) or secondary adenovirus receptors (integrins a5b1, avb3, avb5). FACScan analysis revealed a reduced expression level of CAR and integrin a5b1 in HeLa and U87MG cells after treatment with dexamethasone (Table 1, Figure 2a) . Expression of FACScan-detectable CAR slightly decreased in HeLa cells by 9% and decreased significantly in U87MG cells by 59%. Downregulation of CAR expression took place on the transcriptional level as confirmed by semi-quantitative RT-PCR analysis ( Figure  2b ). Treatment with dexamethasone resulted in slight reduction of CAR mRNA expression in HeLa cells and significant reduction of CAR mRNA expression in U87MG cells (Figure 2b) . In contrast to CAR expression, the expression level of integrins avb3 and avb5 increased by dexamethasone in U87MG cells (Table 1) due to significantly increased expression of av integrin mRNA ( Figure 2b ). Further posttranscriptional and postranslational mechanisms of integrin regulation cannot be excluded. No expression of integrin avb3 was observed in HeLa cells, which lack expression of the integrin b3 subunit (Table 1, Figure 2b ).
TNFa modulates adenovirus receptor expression and adenoviral gene transfer
Dexamethasone activates the cellular glucocorticoid receptor, which is known to inhibit NF-kB activity by direct and indirect mechanisms. 10 TNFa is a potent physiological activator of NF-kB. 21 We tested the effect of TNFa on the expression level of CAR and integrins in Figure 1 Influence of dexamethasone on adenoviral transgene expression. The indicated cell lines were incubated overnight with 100 nM dexamethasone (filled bars) including 0.01% ethanol from stock solution or 0.01% ethanol as a control (empty bars). Cells were incubated for 2 h with a bgalactosidase-expressing adenovirus (AdGal) at MOI 10 (HeLa, OV-UL-2) or MOI 50 (SiHa, U87MG). After transduction, no dexamethasone was present. Cell extracts were analysed 24 h after transduction for bgalactosidase activity using chromogenic substrate ortho-nitrophenyl-b-D-galactoside (ONPG). b-Galactosidase activity was calculated as optical density at 405 nm per mg protein of the corresponding cell extract. All experiments were performed in duplicate. Table 2 ). In all tested cell lines, a significant increase in the expression level of integrins a5b1 and avb3 was observed after treatment with TNFa.
We next tested the effect of TNFa treatment on adenoviral gene transfer in U87MG, HeLa and several ovarian cancer cell lines. Adenoviral transgene expression increased in all tested cell lines when pretreated with TNFa ( Figure 3 ). Increased adenoviral transgene expression by pretreatment with TNFa was most prominent in the highly transduction-resistant, avb3 integrin-lacking cell line A2780. In this cell line, TNFa caused induction of avb3 integrin expression in addition to upregulation of CAR expression (Table 2) .
To investigate whether reduced or increased CAR mRNA expression was by inhibition or activation of the NF-kB transcription factor, HeLa cells were transfected with expression plasmids for either the NF-kB transcriptional p65 subunit or the NF-kB inhibitor IKB. Transfection efficiencies of HeLa cells using Lipofectamin 2000 (Invitrogen) were up to 80% as analysed by using a b-galactosidase-expressing control plasmid (not shown). FACScan analysis revealed no changes in CAR expression level in HeLa cells after transfection of p65 or IKB expression plasmids (not shown), albeit significant overexpression of p65 or IKB, respectively, were detectable by Western blot analysis (not shown).
TGFb modulates expression of primary and secondary adenovirus receptors
Modulation of adenoviral gene transfer by TNFa prompted us to test other integrin-modulating cytokines for their effect on the expression of CAR, integrins and adenoviral gene transfer efficiency. HeLa and OV-UL-2 cells were treated for 48 h with 10 ng/ml TGFb and analysed by FACScan analysis for the expression of CAR and integrins (Table 3) . In contrast to TNFa, having no effect on cell proliferation or morphology in HeLa or OV-UL-2 cells, TGFb slightly reduced cell proliferation in HeLa or OV-UL-2 cells (see below) and induced a slight morphological transition to a more spindle-like cell shape (not shown). TGFb increased expression of integrins avb3 and avb5 in OV-UL-2 cells and induced expression of integrin a5b1, which was not expressed in the absence of TGFb (Table 3) . Semi-quantitative RT-PCR analysis revealed that expression of a5b1 in OV-UL-2 was due to induction of a5 integrin mRNA expression ( Figure 4a ). TGFb had no effect on CAR expression in HeLa cells but reduced CAR expression level in OV-UL-2 cells (Table 3) . Adenoviral gene transfer into OV-UL-2 cells, but not into HeLa cells, decreased by pretreatment with TGFb ( Figure 4b ).
We next tested whether reduced adenoviral gene transfer into OV-UL-2 cells by TGFb would result in decreased cell killing efficiency of a p53-expressing adenoviral vector (ACNp53). OV-UL-2 cells were incubated with ACNp53 and analysed for the number of surviving cells 72 h after transduction. In the absence of ACNp53, TGFb slightly reduced cell proliferation in OV-UL-2 cells when compared to control cells or TNFatreated cells ( Figure 5 ). Addition of ACNp53 at MOI 10 reduced the number of surviving cells to 35% of control cells. The total number of surviving cells in TGFb-treated or control cells did not significantly change after addition of ACNp53. Still, the relative amount of cells surviving ACNp53 treatment in TGFb-treated cells (48%) was higher than in control cells (35%). In contrast, pretreatment of OV-UL-2 cells with TNFa, which increased adenoviral transgene expression in all tested cell lines (see Figure 3) , significantly reduced the percentage of surviving cells to 13% ( Figure 5 ). Regulation of CAR expression and localization A Brüning and IB Runnebaum
CAR is localized at cell-cell adhesions of human cancer cells
To study the subcellular localization of CAR and integrins in human cancer cells, OV-UL-2 cells were coimmunostained for CAR and integrin b3 and analysed by confocal image analysis. Immunostaining for CAR and the integrin b3 subunit revealed a differential localization of CAR at cell-cell contacts ( Figure 6a ) and a more even distribution pattern of b3 integrin (not shown). Enrichment of CAR at cell-cell contact sites was also observed in cell-cell contact-forming HeLa ( Figure  6b ), OV-MZ-31 ( Figure 6c ), and OV-MZ-33 cells ( Figure  6d ). In singular, non-cell-cell contact-forming cancer cells, CAR staining was found evenly spread over the entire cell membrane (not shown).
Trypsinization of cancer cells enhances adenoviral gene transfer
Regionalization Regulation of CAR expression and localization A Brüning and IB Runnebaum from 37% in control cells to 19% in cells trypsinized before application of ACNp53 (Figure 7b ).
Discussion
The cellular uptake of adenoviruses relies on the presence of both CAR as primary and integrins as secondary adenovirus receptors. 12 While the physiological function and localization of integrins has been studied in great detail, 22 little is known about the subcellular distribution, cellular function, and regulation of CAR.
The expression level of CAR in human and murine tissues can vary tremendously 3, 23 and was found to be highly regulated during murine development. 24, 25 In the developing mouse brain, CAR expression peaked in the brains of newborn mice and transfection of murine CAR cDNA increased cell-cell adhesion of murine glioma cells. 25 Previous immunofluorescence studies on lung epithelial tissue cells revealed restriction of CAR to basolateral membranes, with immunostaining most prominently at cell-cell adhesive structures 6 and tight junctions. 7 For human cancer cells, CAR has been shown to be homogeneously distributed throughout the cell membrane. 26, 27 In these studies, cells were either stained as singular cells or under non-cell-cell contact-forming conditions. 26, 27 The same staining pattern was observed on singular cancer cells or on viable cancer cells immunostained at low temperatures, a condition where formation of cell-cell contacts was reduced. When cancer cells were prefixed before immunostaining for CAR, we observed an obvious enrichment of CAR at cell-cell contacts.
Redistribution of CAR from cell-cell contacts to an overall homogeneous membrane distribution as achieved by trypsinization increased adenoviral gene transfer into cancer cells. We observed that in compact spheroidal cancer cell aggregates grown on extracellular matrix gel or soft agar, adenoviral transgene expression was significantly reduced when compared to that of monolayer cells (not shown). This resistance explains the need for relatively high adenoviral titers to be repetitively applied in clinical studies, associated with severe inflammatory side reactions.
Inflammatory reaction against the viral vector is one of the main toxicity problems observed in clinical trials with recombinant adenoviral vectors. [18] [19] [20] Dexamethasone is routinely used as an anti-inflammatory supportive drug, particularly when gene therapeutic approaches are combined with chemotherapy. Transcriptional downregulation of CAR expression by dexamethasone in vitro negatively interfered with the efficiency of adenoviral gene transfer in this study. Dexamethasone should be considered as an agent reducing adenoviral transduction efficiencies also in the clinical setting.
TNFa increased adenoviral gene transfer into U87MG cells despite downregulation of CAR expression and induced significant upregulation of integrins a5b1, avb3 and avb5. This suggests that low CAR protein expression in human cancer cells can be compensated by enhanced integrin expression. In dexamethasone-treated U87MG cells, as well as in TGFb-treated OV-UL-2 cells, upregulation of integrins was less than in TNFa-treated U87MG cells and did not compensate for reduced CAR expression.
The expression levels of CAR and RGD-binding integrins are important factors for adenoviral transduction and their expressional modulation by dexamethasone, TNFa and TGFb may be responsible for changes in adenoviral transgene expression, as observed by us. Despite this, we cannot exclude additional effects of these molecules on other cellular processess involved in adenoviral infection or response to apoptotic stimuli. However, enhanced adenoviral transgene expression by TNFa, caused by upregulation of adenovirus receptors or other processes, and enhanced cell killing efficiency of a p53-expressing adenovirus even in cell lines otherwise not responding to TNFa should be of clinical interest.
We and others have taken cancer tissue biopsies to preassess individual adenoviral transduction efficiencies and to screen for patients who will most beneficially profit from gene therapeutic trials. Expressional regulation of CAR and integrins by TNFa, TGFb and probably other cytokines present at the cancer site suggests that the capability of cancer cells to be transduced under cell culture conditions can significantly differ from in situ conditions. The expression of integrins will be generally higher in situ due to high levels of cytokines enhancing or even inducing integrin expression as shown here for several cancer cell lines. Therefore, already successfully 
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A Brüning and IB Runnebaum applied retargeting of adenoviral vectors to integrins, 26, 28, 29 independent of CAR expression and its localization, can be a promising tool for more efficient gene transfer efficiencies into human cancer cells.
Application of cytokines enhancing expression of CAR and integrins preferentially with anti-tumoral activity can contribute to a better therapeutic efficacy in gene therapeutic applications. The extensive use of dexamethasone should be reconsidered during clinical application of adenoviral vectors due to its potential negative effect on CAR and integrin a5b1 expression.
Materials and methods
Cell lines and cell culture
Cervical carcinoma cell lines HeLa (CCL-2) and SiHa (HTB-35), glioblastoma cell line U87MG (HTB-14) were available from the American Type Culture Collection. Ovarian carcinoma cell line A2780 (ECACC 93112519) was available from the European Collection of Cell Cultures. The human ovarian carcinoma cell lines OV-MZ-30, OV-MZ-31, OV-MZ-33 and OV-UL-2 have been described previously. 17 Cells were cultured in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal calf serum, 100 mg streptomycin per ml, 100 U penicillin G per ml and 2 mM glutamine at 371C in a humidified atmosphere with 5% CO 2.
Adenovirus production and adenoviral transduction analysis
For monitoring adenoviral transduction efficiency, a p53-(ACNp53) 30 or b-galactosidase-expressing adenovirus of serotype 5 (AdGal) 30 was employed. Cells were seeded at a cell density of 1 x 10 5 cells in 24-wells (1.9 cm 2 ) and incubated the following day for 2 h with different titers of AdGal or ACNp53 in serum-free DMEM at 371C. bGalactosidase activity was determined after a 24 h incubation under standard cell culture conditions. Enzymatic activity of b-galactosidase activity was determined by cleavage of chromogenic substrate ONPG (orthonitrophenyl-b-D-galactopyranoside; BioMol). Cells were lysed at 41C in cell culture lysis buffer (25 mM potassium phosphate, pH 7.8, 8 mM MgCl 2 , 1 mM DTT, 1 mM EDTA, 1% Triton-X-100, and 15% glycerol). In total, 50 ml of centrifuged cell lysate were mixed with equal volume of two-times reaction buffer (200 mM sodium phosphate, pH 7.4; 2 mM MgCl 2 ; 1 mM DTT and 1.33 mg/ml ONPG) in a 96-well microtiter plate. Reaction was incubated at 371C until production of a yellow reaction product became visible. Reaction was stopped by addition of 150 ml 1 M basic Tris solution. Absorbance was read at 420 nm in a microplate reader (SPEKTRAmax Plus; Molecular Devices) and related to the protein concentration of the corresponding cell lysate determined by the Bradford assay as described by the supplier (BioRad). Untransduced cells were used as a control and subtracted as background activity during measurement of optical density. All experiments were performed in duplicate and expressed as mean values. For histochemical staining of b-galactosidase activity, cells were grown on glass cover slips, fixed for 5 min with 1% formaldehyde in PBS and subsequently stained with 0.04% X-Gal (Biomol) in PBS with 1 mM MgCl 2 and 5 mM potassium ferri/ferro cyanide.
AdGal was propagated in HEK 293 cells and adenoviral titer was determined by the cytopathic effect assay.
Semi-quantitative RT-PCR analysis
Semi-quantitative RT-PCR analysis of CAR and b-actin has recently been described. 17 In brief, a 195 bp PCR product from the CAR cDNA was amplified using primer pair GCAGGAGCCATTATAGGAACTTTG/ GGACCCCAGGGATGAATGAT and b-actin primers (Stratagene) for co-amplification of a 661 bp product from the b-actin cDNA as an internal standard. PCR conditions for amplification were 3 min at 941C, followed by 27 cycles of 94, 55 and 721C for 1 min each and an extension of 10 min at 721C. For RT-PCR analysis of integrins, the following primer and cycle conditions were used. Integrin av: GAAGATGTTGGGCCAGTTGT/ TCCACAACCCAAAGTGTGAA (571C, 24 cycles; 381 bp), integrin a5: TGTGCTGGAACTCAGCTGTC/ GATTCGGTAGGGCATCTTCA (501C, 36 cycles; 317 bp), integrin b1: GCGAGTGTGGTGTCTGTAAG/ GGACACTCTGGATTCTCCAC (571C, 25 cycles; 334 bp), integrin b3: GCAAGTACTGCGAGTGTGAC/ CCCGGTCAAACTTCTTACAC (571C, 30 cycles; 314 bp), integrin b5: AGCACCAAGAGAGATTGCGT/ GGTGTTTCCACACTCTGGCT (571C, 27 cycles; 246 bp).
Fluorescence-activated cell scanning
Cells were briefly trypsinized, washed with PBS and incubated for 1 h at 41C with the indicated primary antibodies against CAR or integrins in DMEM/2% FCS. Monoclonal antibody RmcB against CAR 31 was used at a dilution of 1:200, monoclonal antibody JBS5 (Chemicon) against integrin a5b1 at a 1:200 dilution, monoclonal antibody 23C6 (Chemicon) against integrin avb3 at a dilution of 1:50 and monoclonal antibody P1F6 (Chemicon) against integrin avb5 at a dilution of 1:200. All integrin antibodies are directed against an extracellular native epitope of the corresponding integrin heterodimers. Cells were washed with PBS and incubated with a Cy2-conjugated donkey anti-mouse antibody (Jackson Immunoresearch) at a dilution of 1:500 for 45 min at 41C. Cells were washed with PBS and subjected to FACScan analysis (Perkin-Elmer). Measured fluorescence intensities were subtracted by the fluorescence intensity of a control incubation of the corresponding cell line with the Cy2-conjugated secondary antibody alone.
Immunofluorescence analysis
Cells grown on glass cover slips were washed with PBS and prefixed for 1 min with -201C methanol. After washing with PBS, cells were incubated for 1 h at room temperature with monoclonal anti-CAR RmcB antibody at a dilution of 1:400 in DMEM/2% FCS. Cells were subsequently washed with PBS and incubated for 45 min at room temperature with a 1:500 diluted Cy3-conjugated donkey anti-mouse antibody (Jackson Immunoresearch). For staining of b3 integrin, cells were incubated with a goat anti-b3 integrin antibody (Santa Cruz Biotech), followed by a FITC-anti-goat antibody (Jackson Immunoresearch). Glass cover slips were embedded in Vectashield VC-1000 (Alexis) and analysed with a Zeiss LSM confocal microscope. 
